Precision-oncology data layer after a Phase 3 mRNA vaccine win

Conviction: 70% · Horizon: 3Y · 2026-08-19
Tempus is still a $20B business trading near $10B

Tempus Data and Applications is generating about $400M of FY26 revenue at roughly 40% growth and 73% gross margins, a SaaS-like profile that typically commands 12-15x sales, or $4.8-6B. Diagnostics is producing about $1.2B, and a conservative 10x versus Guardant at 13x adds $12B, for an $18-20B sum-of-the-parts versus just over $10B today. A successful Phase 3 personalized mRNA cancer vaccine from Moderna and Merck raises the strategic value of the genomic data, diagnostics, and MRD layer Tempus already supplies to that ecosystem.

Instrument Side Target Reason
TEM Long The Data and Applications franchise already looks like a high-growth, high-margin software business, and the diagnostics book is large enough to support a double-digit sales multiple even after a haircut to Guardant. Together that still implies roughly twice the current market cap, while a commercial path for personalized mRNA vaccines increases demand for the genomic and monitoring infrastructure Tempus already operates.

Themes

The content on this page is for informational purposes only and does not constitute financial advice. Stoquate is not a licensed financial advisor. Always conduct your own research and consult a qualified professional before making any investment decisions.